STOCK TITAN
  1. Home
  2. Sec-filings
  3. OCGN
  4. [Form 4] Ocugen, Inc. Insider Trading Activity

Director at Ocugen (NASDAQ: OCGN) awarded 170,100 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Ocugen, Inc. director Junge Zhang received a grant of stock options on June 11, 2026 as part of equity compensation. The award covers 170,100 options to buy common stock at an exercise price of $1.22 per share, expiring on June 11, 2036. The options vest on the earlier of June 11, 2027 or Ocugen’s next annual meeting of stockholders, contingent on continued service through the vesting date. Following this grant, the filing shows Zhang holding 170,100 derivative securities directly, with no open‑market purchases or sales reported.

Positive

  • None.

Negative

  • None.
Insider Zhang Junge
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 170,100 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 170,100 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 170,100 options Stock Option (Right to Buy) grant on June 11, 2026
Exercise price $1.22 per share Conversion/exercise price for granted options
Expiration date June 11, 2036 Option expiration for this grant
Underlying shares 170,100 shares Common stock underlying the options
Holdings after grant 170,100 derivative securities Total options held following this transaction
Vesting date trigger Earlier of June 11, 2027 or next annual meeting Vesting condition from footnote
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
exercise price financial
"conversion_or_exercise_price: "1.2200""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vests financial
"The option vests upon the earlier of (a) June 11, 2027 or (b) Ocugen, Inc.'s next annual meeting"
annual meeting of stockholders financial
"Ocugen, Inc.'s next annual meeting of stockholders"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Zhang Junge
(Last)(First)(Middle)
C/O OCUGEN, INC.
11 GREAT VALLEY PARKWAY
(Street)
MALVERN PENNSYLVANIA 19355
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Ocugen, Inc. [ OCGN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$1.2206/11/2026A170,100 (1)06/11/2036Common Stock170,100$0170,100D
Explanation of Responses:
1. The option vests upon the earlier of (a) June 11, 2027 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date.
/s/ Shankar Musunuri, attorney-in-fact06/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Ocugen (OCGN) report for Junge Zhang?

Ocugen reported a stock option grant to director Junge Zhang. He received 170,100 options to buy common stock as equity compensation, recorded as an acquisition rather than an open-market purchase or sale.

How many Ocugen (OCGN) stock options were granted to Junge Zhang?

Junge Zhang was granted 170,100 stock options. Each option gives the right to buy one share of Ocugen common stock, forming his entire reported derivative position following this transaction in the Form 4.

What is the exercise price of Junge Zhang’s Ocugen (OCGN) stock options?

The exercise price for the granted options is $1.22 per share. This is the price at which Zhang can purchase Ocugen common stock if he exercises the 170,100 options in the future.

When do Junge Zhang’s Ocugen (OCGN) options vest according to the Form 4?

The options vest on the earlier of June 11, 2027 or Ocugen’s next annual meeting of stockholders. Vesting is conditioned on Zhang’s continued service with the company through the relevant vesting date.

When do the Ocugen (OCGN) stock options granted to Junge Zhang expire?

The granted stock options expire on June 11, 2036. After that expiration date, Zhang would no longer be able to exercise these options to purchase Ocugen common stock at the $1.22 exercise price.

Did Junge Zhang buy or sell Ocugen (OCGN) shares on the open market?

The Form 4 shows a grant of stock options classified as an acquisition, not an open-market trade. There are no reported open-market purchases or sales of Ocugen common stock by Zhang in this filing.